S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in
NASDAQ:SURF

Surface Oncology Stock Forecast, Price & News

$8.44
-0.65 (-7.15 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.30
Now: $8.44
$9.09
50-Day Range
$9.03
MA: $11.28
$13.82
52-Week Range
$1.38
Now: $8.44
$14.40
Volume1.31 million shs
Average Volume1.29 million shs
Market Capitalization$343.31 million
P/E RatioN/A
Dividend YieldN/A
Beta2.09
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and the Merck Sharp & Dohme Corp. to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDAÃ (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Surface Oncology logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SURF
CUSIPN/A
CIKN/A
Phone617-714-4096
Employees49
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.36 million
Book Value$2.03 per share

Profitability

Net Income$-54,790,000.00

Miscellaneous

Market Cap$343.31 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.34 out of 5 stars

Medical Sector

640th out of 1,957 stocks

Biological Products, Except Diagnostic Industry

89th out of 177 stocks

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$8.44
-0.65 (-7.15 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SURF News and Ratings via Email

Sign-up to receive the latest news and ratings for SURF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Surface Oncology (NASDAQ:SURF) Frequently Asked Questions

Is Surface Oncology a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Surface Oncology stock.
View analyst ratings for Surface Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Surface Oncology?

Wall Street analysts have given Surface Oncology a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Surface Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Surface Oncology?

Surface Oncology saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 1,600,000 shares, a drop of 25.6% from the December 31st total of 2,150,000 shares. Based on an average daily trading volume, of 1,250,000 shares, the short-interest ratio is currently 1.3 days.
View Surface Oncology's Short Interest
.

When is Surface Oncology's next earnings date?

Surface Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Surface Oncology
.

How were Surface Oncology's earnings last quarter?

Surface Oncology, Inc. (NASDAQ:SURF) posted its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.01.
View Surface Oncology's earnings history
.

How has Surface Oncology's stock price been impacted by Coronavirus?

Surface Oncology's stock was trading at $2.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SURF stock has increased by 256.1% and is now trading at $8.44.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SURF?

4 brokers have issued 12 month price objectives for Surface Oncology's shares. Their forecasts range from $9.00 to $15.00. On average, they expect Surface Oncology's stock price to reach $12.00 in the next year. This suggests a possible upside of 42.2% from the stock's current price.
View analysts' price targets for Surface Oncology
or view top-rated stocks among Wall Street analysts.

Who are Surface Oncology's key executives?

Surface Oncology's management team includes the following people:
  • Mr. Daniel S. Lynch, Exec. Chairman (Age 63, Pay $67.5k)
  • Mr. J. Jeffrey Goater, CEO, Pres & Director (Age 46, Pay $775.47k)
  • Dr. Vito J. Palombella, Chief Scientific Officer (Age 58, Pay $550.47k)
  • Dr. Robert W. Ross, Chief Medical Officer (Age 46, Pay $549.75k)
  • Ms. Jessica Fees, Sr. VP of Fin. & Treasurer (Age 48)
  • Ms. Liisa I. Nogelo, Sec., Chief Compliance Officer & Chief Legal Officer (Age 49)
  • Ms. Lisa McGrath, Sr. VP of HR
  • Ms. Wendy Dwyer, Chief Bus. Officer (Age 47)
  • Mr. Bob Steininger, Sr. VP of Chemistry, Manufacturing & Controls
  • Ms. Alison O'Neill, Sr. VP of Clinical Devel.

What is Jeff Goater's approval rating as Surface Oncology's CEO?

5 employees have rated Surface Oncology CEO Jeff Goater on Glassdoor.com. Jeff Goater has an approval rating of 100% among Surface Oncology's employees. This puts Jeff Goater in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Surface Oncology's key competitors?

What other stocks do shareholders of Surface Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Pfizer (PFE), CrowdStrike (CRWD), QUALCOMM (QCOM), Fastly (FSLY), Intel (INTC), Momo (MOMO), NVIDIA (NVDA), U.S. Xpress Enterprises (USX), Xilinx (XLNX) and Genocea Biosciences (GNCA).

When did Surface Oncology IPO?

(SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI acted as the underwriters for the IPO.

What is Surface Oncology's stock symbol?

Surface Oncology trades on the NASDAQ under the ticker symbol "SURF."

Who are Surface Oncology's major shareholders?

Surface Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Atlas Venture Associates IX LLC (7.24%), Morgan Stanley (2.64%), Acuta Capital Partners LLC (2.46%), BlackRock Inc. (2.34%), Victory Capital Management Inc. (0.93%) and Verition Fund Management LLC (0.72%). Company insiders that own Surface Oncology stock include David S Grayzel, Jeff Goater, Jessica Fees and Robert W Ross.
View institutional ownership trends for Surface Oncology
.

Which institutional investors are selling Surface Oncology stock?

SURF stock was sold by a variety of institutional investors in the last quarter, including Atlas Venture Associates IX LLC, Acuta Capital Partners LLC, Victory Capital Management Inc., Jane Street Group LLC, and HighVista Strategies LLC. Company insiders that have sold Surface Oncology company stock in the last year include David S Grayzel, Jeff Goater, Jessica Fees, and Robert W Ross.
View insider buying and selling activity for Surface Oncology
or view top insider-selling stocks.

Which institutional investors are buying Surface Oncology stock?

SURF stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Caas Capital Management LP, Silverarc Capital Management LLC, Artal Group S.A., Dimensional Fund Advisors LP, Verition Fund Management LLC, and Wells Fargo & Company MN.
View insider buying and selling activity for Surface Oncology
or or view top insider-buying stocks.

How do I buy shares of Surface Oncology?

Shares of SURF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surface Oncology's stock price today?

One share of SURF stock can currently be purchased for approximately $8.44.

How much money does Surface Oncology make?

Surface Oncology has a market capitalization of $343.31 million and generates $15.36 million in revenue each year. The company earns $-54,790,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis.

How many employees does Surface Oncology have?

Surface Oncology employs 49 workers across the globe.

What is Surface Oncology's official website?

The official website for Surface Oncology is www.surfaceoncology.com.

Where are Surface Oncology's headquarters?

Surface Oncology is headquartered at 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139.

How can I contact Surface Oncology?

Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-4096 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.